HealthEquity (NASDAQ:HQY) PT Raised to $94.00 at Guggenheim

HealthEquity (NASDAQ:HQYGet Rating) had its target price lifted by stock analysts at Guggenheim from $89.00 to $94.00 in a report released on Wednesday, The Fly reports. The brokerage currently has a “buy” rating on the stock. Guggenheim’s target price indicates a potential upside of 45.40% from the stock’s current price.

Several other equities analysts also recently issued reports on the stock. Jefferies Financial Group increased their price objective on shares of HealthEquity from $80.00 to $90.00 in a report on Wednesday, November 2nd. Robert W. Baird increased their price objective on shares of HealthEquity from $47.00 to $67.00 and gave the company a “neutral” rating in a report on Wednesday, September 7th. Raymond James raised their price target on shares of HealthEquity from $70.00 to $75.00 and gave the stock an “outperform” rating in a research note on Monday, September 12th. Wells Fargo & Company decreased their price target on shares of HealthEquity from $104.00 to $101.00 and set an “overweight” rating on the stock in a research note on Wednesday. Finally, The Goldman Sachs Group raised shares of HealthEquity from a “sell” rating to a “neutral” rating and raised their price target for the stock from $64.00 to $77.00 in a research note on Friday, October 21st. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $78.14.

HealthEquity Stock Down 2.3 %

HQY opened at $64.65 on Wednesday. The company has a market cap of $5.46 billion, a price-to-earnings ratio of -92.36, a PEG ratio of 3.56 and a beta of 0.81. HealthEquity has a 52-week low of $38.53 and a 52-week high of $79.20. The firm’s fifty day simple moving average is $68.75 and its two-hundred day simple moving average is $65.36.

HealthEquity (NASDAQ:HQYGet Rating) last posted its quarterly earnings data on Tuesday, September 6th. The company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.01). The company had revenue of $206.14 million for the quarter, compared to analysts’ expectations of $203.40 million. HealthEquity had a negative net margin of 7.07% and a positive return on equity of 2.83%. During the same period in the previous year, the business earned $0.21 earnings per share. On average, research analysts forecast that HealthEquity will post 0.69 EPS for the current year.

Insiders Place Their Bets

In other HealthEquity news, EVP Larry L. Trittschuh sold 11,526 shares of HealthEquity stock in a transaction dated Thursday, October 13th. The shares were sold at an average price of $70.00, for a total transaction of $806,820.00. Following the transaction, the executive vice president now directly owns 27,961 shares of the company’s stock, valued at $1,957,270. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other HealthEquity news, EVP Delano Ladd sold 5,897 shares of HealthEquity stock in a transaction dated Friday, October 21st. The shares were sold at an average price of $75.00, for a total transaction of $442,275.00. Following the completion of the sale, the executive vice president now directly owns 37,471 shares in the company, valued at $2,810,325. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Larry L. Trittschuh sold 11,526 shares of HealthEquity stock in a transaction dated Thursday, October 13th. The shares were sold at an average price of $70.00, for a total transaction of $806,820.00. Following the sale, the executive vice president now owns 27,961 shares of the company’s stock, valued at $1,957,270. The disclosure for this sale can be found here. Insiders have sold 46,648 shares of company stock valued at $3,355,690 over the last ninety days. Company insiders own 2.80% of the company’s stock.

Institutional Investors Weigh In On HealthEquity

A number of institutional investors have recently made changes to their positions in HQY. BlackRock Inc. grew its holdings in shares of HealthEquity by 4.0% in the first quarter. BlackRock Inc. now owns 9,423,008 shares of the company’s stock valued at $635,488,000 after purchasing an additional 358,743 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of HealthEquity by 0.4% in the third quarter. Vanguard Group Inc. now owns 8,173,889 shares of the company’s stock valued at $549,041,000 after purchasing an additional 31,009 shares in the last quarter. Wasatch Advisors Inc. grew its holdings in shares of HealthEquity by 3.3% in the first quarter. Wasatch Advisors Inc. now owns 7,638,935 shares of the company’s stock valued at $515,170,000 after purchasing an additional 244,868 shares in the last quarter. FMR LLC grew its holdings in shares of HealthEquity by 11.6% in the second quarter. FMR LLC now owns 3,589,800 shares of the company’s stock valued at $220,378,000 after purchasing an additional 373,264 shares in the last quarter. Finally, State Street Corp grew its holdings in shares of HealthEquity by 2.8% in the third quarter. State Street Corp now owns 2,671,946 shares of the company’s stock valued at $179,475,000 after purchasing an additional 74,035 shares in the last quarter. 99.43% of the stock is currently owned by institutional investors and hedge funds.

HealthEquity Company Profile

(Get Rating)

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

Featured Stories

The Fly logo

Analyst Recommendations for HealthEquity (NASDAQ:HQY)

Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.